BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol 2017;52:1550-7. [PMID: 29082671 DOI: 10.1002/ppul.23884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Mcgarry ME, Gibb ER, Oates GR, Schechter MS. Left Behind: The Potential Impact of CFTR Modulators on Racial and Ethnic Disparities in Cystic Fibrosis. Paediatric Respiratory Reviews 2021. [DOI: 10.1016/j.prrv.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Oates GR, Schechter MS. Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better. Ann Am Thorac Soc 2021;18:215-7. [PMID: 33522873 DOI: 10.1513/AnnalsATS.202010-1274ED] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tumin D, Crowley EM, Li SS, Wooten W, Ren CL, Hayes D Jr. Patterns of Health Insurance Coverage and Lung Disease Progression in Adolescents and Young Adults with Cystic Fibrosis. Ann Am Thorac Soc 2021;18:290-9. [PMID: 32885982 DOI: 10.1513/AnnalsATS.201911-839OC] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 McGarry ME, Williams WA 2nd, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol 2019;54 Suppl 3:S74-83. [PMID: 31715087 DOI: 10.1002/ppul.24434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]
6 Oates GR, Schechter MS. Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies. Expert Rev Respir Med 2022;:1-14. [PMID: 35705523 DOI: 10.1080/17476348.2022.2090928] [Reference Citation Analysis]
7 Sontag MK, Miller JI, Mckasson S, Gaviglio A, Martiniano SL, West R, Vazquez M, Ren CL, Farrell PM, Mccolley SA, Kellar-guenther Y. Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States. IJNS 2022;8:38. [DOI: 10.3390/ijns8030038] [Reference Citation Analysis]
8 McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol 2021. [PMID: 34672432 DOI: 10.1002/ppul.25733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 McGarry ME, Huang CY, Nielson DW, Ly NP. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. J Cyst Fibros 2021;20:424-31. [PMID: 33162303 DOI: 10.1016/j.jcf.2020.10.002] [Reference Citation Analysis]
10 Zeiger AM, McGarry ME, Mak ACY, Medina V, Salazar S, Eng C, Liu AK, Oh SS, Nuckton TJ, Jain D, Blackwell TW, Kang HM, Abecasis G, Oñate LC, Seibold MA, Burchard EG, Rodriguez-Santana J. Identification of CFTR variants in Latino patients with cystic fibrosis from the Dominican Republic and Puerto Rico. Pediatr Pulmonol 2020;55:533-40. [PMID: 31665830 DOI: 10.1002/ppul.24549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Savant AP, Mccolley SA. Cystic fibrosis year in review 2017. Pediatr Pulmonol 2018;53:1307-17. [DOI: 10.1002/ppul.24081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 McGarry M. Transparency and diversity in cystic fibrosis research. Lancet 2020;396:601. [PMID: 32861304 DOI: 10.1016/S0140-6736(20)30906-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sawicki GS, Van Brunt K, Booth J, Bailey E, Millar SJ, Konstan MW, Flume PA. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros 2021:S1569-1993(21)01300-X. [PMID: 34289939 DOI: 10.1016/j.jcf.2021.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 McColley SA, Martiniano SL, Ren CL, Sontag MK, Rychlik K, Balmert L, Elbert A, Wu R, Farrell PM. Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening. J Cyst Fibros 2022:S1569-1993(22)00628-2. [PMID: 35871976 DOI: 10.1016/j.jcf.2022.07.010] [Reference Citation Analysis]
15 McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. Pediatr Pulmonol 2019;54:1382-90. [PMID: 31144477 DOI: 10.1002/ppul.24377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Palla J, Laguna TA. Management of chronic pulmonary disease in the time of coronavirus disease 2019. Curr Opin Pediatr 2021;33:294-301. [PMID: 33938475 DOI: 10.1097/MOP.0000000000001017] [Reference Citation Analysis]
17 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
18 Januska MN, Marx L, Walker PA, Berdella MN, Langfelder-Schwind E. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. J Genet Couns 2020;29:607-15. [PMID: 32227567 DOI: 10.1002/jgc4.1271] [Reference Citation Analysis]
19 Park JK, Shrivastava A, Zhang C, Pollok BA, Finkbeiner WE, Gibb ER, Ly NP, Illek B. Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models. Front Pediatr 2020;8:536. [PMID: 33014932 DOI: 10.3389/fped.2020.00536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]